Correction to: Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)

Adam L Halberstadt; Landon M Klein; Muhammad Chatha; Laura B Valenzuela; Alexander Stratford; Jason Wallach; David E Nichols; Simon D Brandt

doi:10.1007/s00213-018-5117-z

Correction to: Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)

Psychopharmacology (Berl). 2019 Feb;236(2):809. doi: 10.1007/s00213-018-5117-z.

Authors

Adam L Halberstadt^{1

2}, Landon M Klein³, Muhammad Chatha³, Laura B Valenzuela³, Alexander Stratford⁴, Jason Wallach⁵, David E Nichols⁶, Simon D Brandt⁷

Affiliations

¹ Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0804, USA. ahalberstadt@ucsd.edu.
² Research Service, VA San Diego Healthcare System, 3350 La Jolla Village Dr, San Diego, CA, 92161, USA. ahalberstadt@ucsd.edu.
³ Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0804, USA.
⁴ Synex Synthetics BV, Karveelweg 20, 6222, NH, Maastricht, The Netherlands.
⁵ Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, 600 South 43rd Street, Philadelphia, PA, 19104, USA.
⁶ Division of Chemical Biology and Medicinal Chemistry, University of North Carolina, Genetic Medicine Building, 120 Mason Farm, Road, Chapel Hill, NC, 27599, USA.
⁷ School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK.

PMID: 30443792
DOI: 10.1007/s00213-018-5117-z

Abstract

The author of this article wanted to change the Acknowledgments section to: These studies were supported by an award from NIDA (R01 DA041336), as well as by the Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center. Receptor binding and functional data were generously.

Publication types

Published Erratum